1992
DOI: 10.1016/s0021-9258(19)50384-2
|View full text |Cite
|
Sign up to set email alerts
|

A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
49
0

Year Published

1995
1995
2021
2021

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 327 publications
(51 citation statements)
references
References 38 publications
2
49
0
Order By: Relevance
“…Heparinase was purchased from Sigma Chemical Company (St. Louis, MO). Recombinant human receptorassociated protein (RAP) was produced as a fusion protein and purified as described previously (27). The carboxyl-terminal fragment of human LPL (amino acid residues 313-448) was produced in E. coli as a fusion protein with glutathione S -transferase (GST) as described previously (28) and designated as GST-LPLC.…”
Section: Methodsmentioning
confidence: 99%
“…Heparinase was purchased from Sigma Chemical Company (St. Louis, MO). Recombinant human receptorassociated protein (RAP) was produced as a fusion protein and purified as described previously (27). The carboxyl-terminal fragment of human LPL (amino acid residues 313-448) was produced in E. coli as a fusion protein with glutathione S -transferase (GST) as described previously (28) and designated as GST-LPLC.…”
Section: Methodsmentioning
confidence: 99%
“…The appropriate delivery of members of the LDL receptor family to the cell surface requires the 39 kDa RAP. RAP is an ER resident protein (Strickland et al, 1991) that binds tightly to members of the LDL receptor family and prevents them from associating with other ligands (Herz et al, 1991;Williams et al, 1992). RAP associates with LRP early in the secretory pathway, reducing its ligand binding capacity, and then dissociates from LRP at the lower pH encountered in the Golgi (Bu et al, 1995).…”
Section: Introductionmentioning
confidence: 99%
“…RAP was described as a molecular chaperone for LRP1 and antagonist for its interactions with ligands ( 16 , 17 , 18 ). This indicates that RAP may also serve the chaperone function for other LDLR family receptors, which is supported by several studies ( 19 , 20 , 21 , 22 ).…”
mentioning
confidence: 99%